Last reviewed · How we verify
Adefor dipivoxil
Adeforvir dipivoxil is a nucleotide reverse transcriptase inhibitor that blocks viral replication in hepatitis B by inhibiting the reverse transcriptase enzyme.
Adeforvir dipivoxil is a nucleotide reverse transcriptase inhibitor that blocks viral replication in hepatitis B by inhibiting the reverse transcriptase enzyme. Used for Chronic hepatitis B infection.
At a glance
| Generic name | Adefor dipivoxil |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Nucleotide reverse transcriptase inhibitor |
| Target | Hepatitis B virus reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Virology / Hepatology |
| Phase | FDA-approved |
Mechanism of action
Adefovir dipivoxil is a prodrug that is converted to adefovir in vivo, which then acts as a nucleotide analog inhibitor of hepatitis B virus (HBV) reverse transcriptase. It prevents viral DNA synthesis and replication, thereby reducing HBV viral load and improving liver function in chronic hepatitis B patients.
Approved indications
- Chronic hepatitis B infection
Common side effects
- Nephrotoxicity / renal dysfunction
- Headache
- Asthenia
- Abdominal pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adefor dipivoxil CI brief — competitive landscape report
- Adefor dipivoxil updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI